SCHEMBL9210673

SCHEMBL9210673

CC(C)(c1ccccc1)[Si](C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 3/20 0.42
TAAR1 Q96RJ0 1/20 0.42
ALOX15 P16050 1/20 0.42
ESR1 P03372 2/20 0.41
ESR2 Q92731 2/20 0.41
CYP3A4 P08684 1/20 0.41
KCNN4 O15554 4/20 0.40
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 2/20 0.39
CYP2C19 P33261 1/20 0.38
HIF1A Q16665 1/20 0.38
CYP2B6 P20813 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC10 Q969S8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10633204 0.83 TAAR1 (0.48) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL7053156 0.79 ALDH1A1 (0.44) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL22730177 0.79 MAPK1 (0.42) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL22730200 0.79 MAPK1 (0.42) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL6404468 0.79 ESR1 (0.43) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL6404472 0.79 ALDH1A1 (0.44) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL10633132 0.79 MAPK1 (0.42) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL7526293 0.77 MAPK1 (0.41) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL8741645 0.76 MAPK1 (0.44) MAPK1ALDH1A1TAAR1ALOX15ESR1
SCHEMBL8741663 0.76 MAPK1 (0.44) MAPK1ALDH1A1TAAR1ALOX15ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230253626-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2023-08-10 US disclosed
US-11700765-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2023-07-11 US disclosed
WO-1995009845-A1 PYRIMIDINYL-GLUTAMIC ACID DERIVATIVES ELI LILLY AND COMPANY (US) 1995-04-13 WO disclosed
EP-0567223-A1 Glutamic acid derivatives as antineoplastic agents ELI LILLY AND COMPANY (US) 1993-10-27 EP disclosed
US-5196424-A Antitumor ELI LILLY AND COMPANY (US) 1993-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11700765-B2 Organic electroluminescent materials and devices SOD1, L1CAM, MCM2 MAPK1 2407/4885ALDH1A1 445/4885TAAR1 2300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.